approvals: T2D (Mounjaro, 2022), obesity (Zepbound, 2023), and obstructive sleep apnea with obesity (Zepbound, 2024) Ongoing Innovations in GLP-1s Landscape The obesity pipeline from phase 1 to market now includes 173 drugs, with GLP-1 and combination therapies accounting for majority of trials
For a medication protocol that requires titration management and side effect oversight, that's a real differentiator from platforms that offer one intake consultation and ship medication without ongoing support
Open Heart 7 , e001337 (2020)
Individual variation is real and significant with research-stage compounds
However, severe vomiting that prevents you from keeping down food or liquids for more than a few hours requires immediate medical attention to rule out other conditions